Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive...

MONDAY, Oct. 28, 2024 -- From 2010 to 2023, there was an increase in prescribing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium...

Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive...

TUESDAY, Nov. 5, 2024 -- In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases,...

Ozempic and other GLP-1 drugs show promise not only in managing obesity and diabetes but also in reducing Alzheimer's risk. A study published in...

THURSDAY, Nov. 7, 2024 -- Expanding access to obesity medications such as glucagon-like peptide 1 (GLP-1) receptor agonists and dual gastric...

TUESDAY, Oct. 29, 2024 -- Among privately insured patients, there was a doubling in the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs)...

Most patients may continue to safely take glucagon-like peptide-1 (GLP-1) receptor agonists as prescribed before undergoing elective surgery and...

FRIDAY, Nov. 1, 2024 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer...

FRIDAY, Nov. 1, 2024 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer...